Biomx

Yahoo Finance • 17 days ago

BiomX announces $3M private placement

BiomX (PHGE) entered into definitive agreements in connection with a private investment in public equity financing for expected gross proceeds of approximately $3M, before deducting placement agent fees and other offering expenses. H.C. Wa... Full story

Yahoo Finance • 18 days ago

BiomX Announces $3.0 Million Private Placement

NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, to... Full story

Yahoo Finance • last month

BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program for Staphylococcus... Full story

Yahoo Finance • 2 months ago

BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026

(RTTNews) - BiomX Inc. (PHGE), a clinical stage biopharmaceutical company, announced that an independent Data Monitoring Committee has completed a safety review of adverse events reported in its Phase 2b trial of BX004 in cystic fibrosis.... Full story

Yahoo Finance • 2 months ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used in the Phase 2b trial An independent Da... Full story

Yahoo Finance • 2 months ago

BiomX Inc. Announces 1-for-19 Reverse Stock Split

NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, to... Full story

Yahoo Finance • 2 months ago

BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections

Earnings Call Insights: BiomX Inc. (PHGE) Q3 2025 MANAGEMENT VIEW * Jonathan Solomon, CEO, stated that the third quarter of 2025 was an important period for BiomX, highlighting that "we began the quarter strongly with first patient dos... Full story

Yahoo Finance • 3 months ago

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

BiomX believes that it has fully addressed the FDA’s queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clarifications on the nebulizer has also be... Full story

Yahoo Finance • 5 months ago

BiomX Inc (NYSEARCA:PHGE) Surges 142% After Stunning Q2 2025 Earnings Beat and Promising BX211 Phase 2 Results

BiomX Inc (NYSEARCA:PHGE [https://www.chartmill.com/stock/quote/PHGE/profile]) reported its second-quarter 2025 financial results, delivering a significant earnings surprise that has fueled a sharp upward movement in its stock price. The c... Full story

Yahoo Finance • 5 months ago

Most active stocks in Wednesday's session

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session. [mostactive] TOP MOST ACTIVE STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/st... Full story

Yahoo Finance • 5 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,... Full story

Yahoo Finance • 6 months ago

BiomX begins phase 2b trial for phage therapy targeting CF infections

NESS ZIONA, Israel - BiomX Inc. (NYSE American:PHGE), a clinical-stage biotech company with a market capitalization of $10.9 million, has initiated patient dosing in its Phase 2b clinical trial evaluating BX004, a phage therapy targeting a... Full story

Yahoo Finance • 2 years ago

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific... Full story

Yahoo Finance • 3 years ago

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific p... Full story

Yahoo Finance • 3 years ago

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

BiomX CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target spe... Full story

Yahoo Finance • 4 years ago

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

Live Webinar Event to be Held on Thursday, May 12th, 11:00 AM EDT BRANFORD, Conn. & NESS ZIONA, Israel, May 06, 2022--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advanc... Full story